{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:43:42Z","timestamp":1781588622583,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100226","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T21:34:51Z","timestamp":1628285691000},"page":"100226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+\/HER2- advanced breast cancer patients with\u00a0poor prognostic factors: data from an international study"],"prefix":"10.1016","volume":"6","author":[{"given":"A.","family":"Davie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cuyun Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ostojic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ringeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100226_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100226_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100226_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1563-2571.2001.01033.x","article-title":"Prognostic significance of liver\u00a0metastases as first site of generalisation in patients with breast cancer \u2013 a retrospective analysis","volume":"28","author":"Baur","year":"2001","journal-title":"Acta Med Austriaca"},{"key":"10.1016\/j.esmoop.2021.100226_bib4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1,038 women with metastatic breast cancer","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/CAD.0b013e32834860af","article-title":"Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005","volume":"22","author":"Geiger","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.esmoop.2021.100226_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2021.100226_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdt539","article-title":"An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients","volume":"25","author":"Regierer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10585-015-9697-2","article-title":"Pattern of metastasis and outcome in patients with breast cancer","volume":"32","author":"Gerratana","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.esmoop.2021.100226_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-018-0094-2","article-title":"Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy","volume":"4","author":"Di Leo","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/tbj.12717","article-title":"Progynostic factors of survival among women with metastatic breast cancer and impact of primary or secondary nature of disease on survival: a French population-based study","volume":"23","author":"Marshall","year":"2017","journal-title":"Breast J"},{"key":"10.1016\/j.esmoop.2021.100226_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prp.2015.11.003","article-title":"Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis","volume":"212","author":"Ren","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.esmoop.2021.100226_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","article-title":"Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis","volume":"161","author":"Leone","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100226_bib14","first-page":"1553","article-title":"Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index","volume":"18","author":"Liu","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12282-011-0320-3","article-title":"Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer","volume":"20","author":"Kawano","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bjc.2016.303","article-title":"Renewed interest in the progesterone receptor in breast cancer","volume":"115","author":"Lim","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10549-015-3432-1","article-title":"Racial differences in outcomes for patients with metastatic breast cancer by disease subtype","volume":"151","author":"Vaz-Luis","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100226_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.prp.2014.01.008","article-title":"Prognostic factors in patients with metastatic breast cancer at the time of diagnosis","volume":"210","author":"Ren","year":"2014","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.esmoop.2021.100226_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib20","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology\u2013breast cancer (NCCN evidence block). Version 2.2020. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed February 5, 2020."},{"key":"10.1016\/j.esmoop.2021.100226_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5306\/wjco.v5.i5.990","article-title":"Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions","volume":"5","author":"Milani","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"29","key":"10.1016\/j.esmoop.2021.100226_bib23","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","article-title":"Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2\u2013negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Partridge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100226_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100226_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib26","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100226_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2021.100226_bib28","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100226_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100226_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100226_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100226_bib32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100226_bib33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib34","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1200\/JCO.2012.47.6952","article-title":"Evaluation of treatment benefit in Journal of Clinical Oncology","volume":"31","author":"Goodwin","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100226_bib37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib38","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.esmoop.2021.100226_bib39","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.clinthera.2017.07.009","article-title":"Patient-reported quality of life and treatment satisfaction in patients with HR(+)\/HER2(-) advanced\/metastatic breast cancer","volume":"39","author":"Wood","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.esmoop.2021.100226_bib40","doi-asserted-by":"crossref","first-page":"e000227","DOI":"10.1136\/esmoopen-2017-000227","article-title":"Patient-reported pain severity, pain interference and health status in HR+\/HER2- advanced\/metastatic breast cancer","volume":"2","author":"Wood","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2021.100226_bib41","first-page":"1","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries","volume":"11","author":"von Moos","year":"2018","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib42","author":"EQ-5D"},{"key":"10.1016\/j.esmoop.2021.100226_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.esmoop.2021.100226_bib44","series-title":"EQ-5D Value Sets: Inventory, Comparative Review and User Guide","year":"2007"},{"key":"10.1016\/j.esmoop.2021.100226_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-6-18","article-title":"EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD)","volume":"6","author":"Grandy","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.esmoop.2021.100226_bib46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100226_bib47","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","article-title":"The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study","volume":"14","author":"Sprangers","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.esmoop.2021.100226_bib49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.283.17.2253","article-title":"Incident type 2 diabetes mellitus in African American and white adults: the atherosclerosis risk in communities study","volume":"283","author":"Brancati","year":"2000","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.esmoop.2021.100226_bib50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/jech.54.11.839","article-title":"Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey","volume":"54","author":"Robbins","year":"2000","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.esmoop.2021.100226_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjmed.2008.09.049","article-title":"Dyslipidemia and the treatment of lipid disorders in African Americans","volume":"122","author":"Taylor","year":"2009","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100226_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12885-020-6527-y","article-title":"Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre","volume":"20","author":"Twelves","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2021.100226_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canep.2016.10.019","article-title":"HR+\/Her2- breast cancer in pre-menopausal women: the impact of younger age on clinical characteristics at diagnosis, disease management and survival","volume":"45","author":"De Camargo Cancela","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.esmoop.2021.100226_bib54","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.esmoop.2021.100226_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcpo.2015.03.002","article-title":"Why have breast cancer mortality rates declined?","volume":"5","author":"Narod","year":"2015","journal-title":"J\u00a0Cancer Policy"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2021.100226_bib56","first-page":"275P","article-title":"First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SysHERs registry [abstract]","volume":"28","author":"Jahanzeb","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100226_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2020.12.012","article-title":"Development of a prognostic factor index among women with HR+\/HER2-metastatic breast cancer in a community oncology setting","author":"Vidal","year":"2021","journal-title":"Clin Breast Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:49Z","timestamp":1761856129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2059702921001873"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100226","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+\/HER2- advanced breast cancer patients with\u00a0poor prognostic factors: data from an international study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100226"}}